Table 1 Clinical characteristics and peri-operative data of patients with prostate cancer who underwent surgery with TIVA-TCI or BAL anaesthesia

Clinical data

Age (yrs)

60.66 (5.91)

62.16 (6.23)

0.31

Venous thromboembolism risk

Highest risk

54 (100%)

48 (100%)

1

Prostate cancer risk*

Intermediate-risk

26 (48.1%)

30 (62.5%)

High-risk

28 (51.8%)

18 (37.5%)

0.17

ASA, n (%):

I

4 (7.4%)

6 (12.5%)

II

50 (92.6%)

42 (87.5%)

0.39

Histological grade of cancer

G2 (Gleason 5–6)

15 (27.8%)

14 (29.2)

G3 (Gleason 7–10)

39 (72.2%)

34 (70.8%)

0.88

pT, n (%)

2

30 (55.6%)

32 (66.7%)

0.25

3

24 (44.4%)

16 (33.3%)

pN, n (%) #

0

17 (85.0%)

24 (96.0%)

0.20

1

3 (15.0%)

1 (4.0%)

Peri-operative data

Type of surgery

LRP

36 (66.7%)

34 (70.8%)

0.65

RALP

18 (33.3%)

14 (29.2%)

Time of anaesthesia (min)

107.5 (16.8)

101.4 (26.2)

0.26

Blood loss (ml)

123.3 (131.1)

121.4 (110.6)

0.81

Total amount of crystalloid received (ml)

468.5 (110.21)

496.8 (198.5)

0.27

Intra-operative body temperature

36.2 (0.3)

36.1 (0.2)

0.83

Intra-operative MAP (mmHg)

104.6 (10.5)

106.2 (10.2)

0.61

Intra-operative SpO2 (%)

96.7 (0.9)

97.8 (1.8)

0.75

Arterial lactate level (mmol/l)

1 h post-surgery

0.7 (0.2)

0.6 (0.4)

0.32

24 h post-sugery

1.7 (0.2)

1.8 (0.2)

0.82

Intra-operative BE (mmol/l)

0.3 (0.4)

0.4 (0.4)

0.62

Intra-operative PaO2 (mmHg)

219.4 (11.2)

216.5 (16.8)

0.72